Median cost parameters and assumed distribution for probability sensitivity analysis, by intervention (constant 2014 US$)
| Interventions | Median (IQR) base case | Distribution for probabilistic sensitivity analysis | Sources |
|---|---|---|---|
| LLIN | |||
| Procurement price, per net | $3.72 ($1.50) | γ | 18 |
| Freight and insurance mark-up | 20% (20%) | γ | 19 |
| In-country delivery mark-up | 48% (20%) | γ | 20 |
| Complementary vector control (costing modelled on IRS) | |||
| Estimated average total cost per person protected per year | $4.24 ($2.25) | γ | 21 |
| IPTp using SP | |||
| Procurement price per dose of 3 SP tablets | $0.17 ($0.20) | γ | 18 |
| In-country delivery mark-up | 15% (20%) | γ | 19 22 |
| Patient delivery cost per dose of 3 tablets | $0.44 ($0.20) | γ | 22 |
| Number of doses | 4 | Point estimate | Key informant interview |
| SMC | |||
| Procurement cost per SP+amodiaquine course | $1.44 ($1.50) | γ | 23 |
| In-country delivery mark-up through public facility, outreach clinics and village health workers | 70% (20%) | γ | 24–27 |
| Number of rounds | 3 | Point estimate | Key informant interview |
| Diagnosis | |||
| Procurement cost per rapid diagnostic test/microscopy slide | $0.60 ($0.30) income groups 1, 2 $0.80 ($0.50) income groups 3, 4 | γ | 28 29 |
| Number of fevers per person per year | 3.50 in U5, 1 in 5+ | Point estimate | Authors' estimation |
| Procurement cost per G6PD deficiency test | $5.00 ($7.00) | γ | Key informant interview |
| In-country delivery mark-up (public health facility) | 15% (20%) | γ | |
| In-country delivery and patient delivery mark-up (communities) | 40% (20%) | γ | 30–33 |
| Treatment Procurement cost per dose of ACT | $0.48 ($0.20) U5 in WB income groups 1, 2 | γ | 28 |
| $0.63 ($0.20) 5+ in WB income groups 3, 4 | |||
| $1.30 ($0.40) in U5 in WB income groups 3, 4 | |||
| $1.70 ($1.00) in 5+ in WB income groups 3, 4 | |||
| Procurement cost per dose of chloroquine and primaquine | $0.83 ($0.20) for U5 and $3.33 ($1.50) in 5+ in WHO WPR and SEAR regions | γ | 18 |
| $0.53 ($0.20) for U5 and $2.13 ($1.50) in 5+ elsewhere | |||
| Procurement cost per dose of ACT and primaquine | $1.07 ($0.50) for U5 and $3.52 ($1.50) in 5+ in WHO WPR and SEAR regions | γ | |
| $1.36 ($1.50) for U5 and $4.69 ($1.50) in 5+ elsewhere | |||
| Procurement cost per dose of quinine | $0.91 ($0.20) in U5 | γ | |
| $3.63 ($1.50) in 5+ | |||
| Procurement cost per dose of injectable artesunate | $5.36 ($1.50) in U5 | ||
| $14.4 ($1.50) in 5+ | |||
| In-country delivery mark-up (public health facility) | 15% (20%) | γ | 19 |
| In-country delivery and patient delivery of diagnosis and treatment (as part of community management) | 55% (20%) | γ | 34–37 |
| Outpatient visit and inpatient stay (range across levels of care/facility type) | Country-specific cost estimates | Uniform | 17 |
| Estimated number of hospital bed day stay for severe malaria episode | 3 | Point estimate | Key informant interviews |
| Surveillance | |||
| Cost of epidemiological and entomological surveillance per person at risk, and malaria surveys | $0.05 ($0.03) | γ | 34–39 |
| Case investigation, per case | $290 ($100) | γ | |
| Proactive case detection, per case | $3.12 ($2.00) | γ | |
| Wastage mark-up | 10% (10%) | γ | 19 22 |
ACT, artemisinin combination therapy; LLIN, long-lasting insecticidal treated nets; G6PD, glucose-6-phosphate dehydrogenase deficiency; IPTp, intermittent preventive treatment in children; IRS, indoor residual spraying; SMC, seasonal malaria chemoprevention in children; SP, sulfadoxine-pyremithamine; WB, World Bank; WPR, Western Pacific Region; SEAR, South-East Asia Region; U5, under-5.